𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors

✍ Scribed by Blackledge, G; Averbuch, S

Book ID
109997914
Publisher
Nature Publishing Group
Year
2004
Tongue
English
Weight
123 KB
Volume
90
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Follicular and epidermal alterations in
Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
✍ R. Van Doorn; G. Kirtschig; E. Scheffer; T.J. Stoof; G. Giaccone 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

We report the cutaneous side-effects of ZD1839 (Iressa), a new anticancer agent that acts by inhibiting epidermal growth factor (EGF) receptor signal transduction. Three patients receiving ZD1839 developed an eruption consisting of follicular papules and pustules in an acneiform distribution as well

Epidermal growth factor receptor (EGFR)
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non-small cell lung cancer
✍ Sae-Won Han; Pil Gyu Hwang; Doo Hyun Chung; Dong-Wan Kim; Seock-Ah Im; Young Tae 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 351 KB 👁 1 views

## Abstract Gefitinib has shown meaningful antitumor activity with tolerable toxicity in chemotherapy‐refractory NSCLC in previous studies. Moreover, EGFR expression failed to show a correlation with response. In an attempt to identify predictive markers of response, we have investigated the tumora